IMAPAC Glossary

Dietary effect on bioavailability evaluates how food intake influences the absorption and systemic exposure of a therapeutic product.

Dietary supplement contamination refers to the unintended presence of harmful substances, impurities or undeclared ingredients within nutritional supplement products.

Differential efficacy subgroup analysis compares treatment responses across predefined patient groups to identify clinically meaningful differences in efficacy.

Differential gene expression analysis identifies genes whose expression levels differ significantly between biological samples, conditions or disease states.

Differential protein expression compares changes in protein abundance between biological samples to identify disease mechanisms, biomarkers and therapeutic responses.

Differential Scanning Calorimetry (DSC) is a thermal analysis technique used to evaluate the stability, folding and thermal behaviour of biological and pharmaceutical materials.

Cell differentiation is the biological process by which unspecialised cells develop into specialised cell types with distinct structures and functions.

Digital health integration connects digital technologies with healthcare systems to improve patient care, data management and clinical decision-making.

Directed evolution is a laboratory technique that mimics natural selection to generate proteins or enzymes with improved or novel properties.

Direct-to-Consumer (DTC) refers to healthcare products or services marketed directly to consumers without relying solely on healthcare professionals.

Disintegration test performance evaluates how rapidly a solid dosage form breaks apart under specified conditions before drug dissolution.

Dispersible tablet design develops tablets that rapidly disperse in water to improve administration, patient convenience and dosing flexibility.

Disposition kinetics characterisation evaluates how a therapeutic product is absorbed, distributed, metabolised and eliminated to understand its behaviour within the body.

A disproportionate adverse event is a safety event reported more frequently than expected, indicating a potential association requiring further pharmacovigilance evaluation.

Dissolution method development establishes analytical procedures for measuring the rate and extent of drug release from pharmaceutical dosage forms.

A dissolution testing protocol defines the procedures used to measure the rate and extent of drug release from a pharmaceutical dosage form.

A distributed development strategy coordinates research, development and manufacturing activities across multiple organisations or geographic locations.

Distribution channels are the systems and pathways used to transport pharmaceutical products from manufacturers to healthcare providers and patients.

DNA damage response activation is the cellular process that detects DNA damage and initiates repair, cell-cycle arrest or apoptosis to maintain genomic integrity.

DNA methylation is an epigenetic modification that regulates gene expression through the addition of methyl groups to specific DNA regions without altering the DNA sequence.

A document archival strategy defines how regulated records are securely stored, protected and retrieved throughout their required retention period.

A document control system manages the creation, review, approval, revision and distribution of regulated documents throughout their lifecycle.

A document retention schedule specifies how long regulated records must be maintained before secure archiving or disposal.

Donor-dependent variability refers to biological differences between donors that influence the quality, consistency and performance of donor-derived materials or therapies.

A dosage adjustment algorithm provides structured recommendations for modifying medicine doses according to patient-specific clinical or pharmacokinetic factors.

Dosage form transition bridging demonstrates that changes between pharmaceutical dosage forms do not adversely affect product safety, efficacy or performance.

Dose escalation is the controlled increase of treatment doses during clinical trials to evaluate safety, tolerability and optimal dosing.

Dose-limiting toxicity (DLT) is an adverse effect severe enough to prevent further dose escalation during clinical development.

Dose-limiting toxicity (DLT) is an adverse effect severe enough to prevent further dose increases during a clinical trial.

Dose proportionality assessment evaluates whether systemic drug exposure increases proportionally with increasing dose over a defined dose range.

Dose-response modelling mathematically describes the relationship between drug dose or exposure and the resulting biological or clinical response.

Downstream processing comprises the purification, recovery and formulation steps required to produce a finished biopharmaceutical product after upstream production.

Drug candidate selection criteria define the scientific and commercial factors used to prioritise compounds for pharmaceutical development.

A drug carrier is a material or delivery vehicle that transports an active pharmaceutical ingredient to improve targeting, stability or controlled release.

A drug delivery system is a formulation or device designed to transport and release a therapeutic agent at the intended site of action.

A drug-disease interaction occurs when an existing disease alters the effectiveness, safety or pharmacokinetic profile of a therapeutic product.

Drug dissolution kinetics characterises the rate and mechanism by which an active pharmaceutical ingredient dissolves from its dosage form.

A drug-drug interaction (DDI) occurs when one medicine alters the effectiveness, metabolism or safety profile of another medicine.

Drug efficacy is the ability of a medicine to produce its intended therapeutic effect under controlled clinical conditions.

Drug interaction potentiation occurs when one medicine enhances the pharmacological effect or toxicity of another beyond its expected activity.

Drug-ligand binding kinetics characterises the rates of association and dissociation between a therapeutic compound and its biological target.

Drug metabolism is the enzymatic conversion of pharmaceutical compounds into metabolites that can be eliminated from the body.

Drug permeability is the ability of a therapeutic compound to cross biological membranes and reach its target tissues.

A drug product is the finished pharmaceutical dosage form containing the active ingredient and all required excipients for patient administration.

Drug product expiration dating establishes the period during which a finished pharmaceutical product is expected to remain safe, effective and within specification.

Drug product quality assurance comprises systematic activities that ensure finished pharmaceutical products consistently meet predefined quality and regulatory requirements.

Drug repurposing is the development of an existing approved or investigational medicine for a new therapeutic indication.

Drug resistance is the reduced effectiveness of a therapeutic agent caused by biological adaptations that limit its activity.

A drug substance is the active pharmaceutical ingredient manufactured before formulation into the final drug product.

A drug substance certificate documents that an active pharmaceutical ingredient complies with predefined quality specifications and manufacturing requirements.

A drug substance impurity strategy defines the identification, control and qualification of impurities to ensure product quality and regulatory compliance.

Drug substance polymorph conversion describes the transformation of an active pharmaceutical ingredient from one crystalline form to another during manufacture or storage.

A dry powder inhaler (DPI) is a handheld device that delivers powdered medication directly to the lungs through inhalation.

A dual antibody is an engineered antibody designed to bind two different antigens or epitopes simultaneously to enhance therapeutic activity.

Durability and stability data demonstrate that a pharmaceutical product maintains its quality, potency and performance throughout its intended shelf life.

Durability of response measures how long a therapeutic benefit is maintained after an initial clinical response has been achieved.

Dynamic light scattering analysis measures particle size distribution by analysing fluctuations in scattered light caused by particles undergoing Brownian motion.

A dynamic population model predicts treatment outcomes by simulating changes within patient populations using biological, clinical and statistical data.

A dysfunction prediction model uses biological, clinical or computational data to estimate the likelihood of disease progression or functional impairment.

Early dose escalation is a clinical development strategy that cautiously increases dose levels in the early stages of a study to evaluate safety and tolerability.

Early Warning System Integration combines monitoring technologies and data sources to detect emerging safety, quality or operational risks at an early stage.

Efficacy is the ability of a therapeutic product to achieve its intended clinical benefit under controlled study conditions.

An efficacy endpoint definition specifies the clinical outcome used to determine whether a therapeutic intervention achieves its intended treatment benefit.

Efficacy Validation Study confirms that a therapeutic intervention consistently achieves its intended clinical benefit under predefined study conditions.

Elastase Assay Performance evaluates the accuracy, sensitivity and reproducibility of assays used to measure elastase enzyme activity or concentration.

Electrokinetic chromatography is a capillary separation technique that combines electrophoretic migration with chromatographic partitioning to separate neutral and charged molecules.

An electronic batch record is a digital manufacturing record that documents production activities, process parameters and quality data throughout batch manufacture.

Electrophoresis is a laboratory technique that separates charged molecules according to their size, charge and migration in an electric field.

ELISA is an antibody-based laboratory assay used to detect and quantify specific proteins, antibodies or other biological molecules.

Elite Athlete Pharmacology examines how medicines influence the physiology, performance and anti-doping considerations of high-performance athletes.

Embryonic Toxicity Risk evaluates the potential of a substance to cause harmful effects on embryo development during pregnancy.

Emergency Protocol Activation initiates predefined emergency procedures to protect patients, personnel and study integrity during unexpected clinical or operational events.

Employment Impact Assessment evaluates how disease or treatment affects an individual's ability to work, productivity and occupational functioning.

Empyema Formation Prevention comprises measures that reduce the risk of pus accumulation within body cavities, particularly the pleural space, following infection.

An enantiomer is one of two mirror-image forms of a chiral molecule that may exhibit different biological or pharmacological properties.

Encapsulation is the process of enclosing an active ingredient within a protective material to improve stability, delivery or controlled release.

Endocrine disruption is the interference of chemicals with normal hormonal signalling, potentially affecting development, reproduction and overall health.

Endocrinology is the medical and scientific study of hormones, endocrine glands and the disorders caused by abnormal hormonal regulation.

Endoscopic Ultrasound Guidance combines endoscopy with ultrasound imaging to improve the diagnosis and guidance of minimally invasive procedures.

Endosomal escape is the process by which therapeutic molecules leave endosomes after cellular uptake to reach their intended intracellular target.

Endotoxin is a lipopolysaccharide from Gram-negative bacterial membranes that can cause severe immune reactions if present in biopharmaceutical products.

Endotoxin testing detects bacterial endotoxins in pharmaceutical products to ensure compliance with safety limits before product release.

An engineered cell line is a genetically modified cell line developed to express desired characteristics for research, manufacturing or therapeutic applications.

Enrolment forecasting predicts participant recruitment rates and timelines to support efficient planning and execution of clinical trials.

Enteral Nutrition Access provides nutritional support through the gastrointestinal tract using feeding tubes when normal oral intake is insufficient or impossible.

Enterobacterial Repetitive Intergenic Sequences (ERIC) are conserved bacterial DNA elements used for molecular typing and strain differentiation.

An environmental monitoring programme systematically monitors manufacturing environments to detect microbial and particulate contamination and maintain controlled conditions.

Enzymatic degradation prevention comprises formulation, process or molecular strategies that minimise enzyme-mediated breakdown of therapeutic products.

Enzymatic Protein Modification alters protein structure or function through enzyme-mediated reactions to improve biological activity, stability or therapeutic performance.

Enzyme Immunoassay Accuracy assesses how reliably an enzyme immunoassay measures the intended analyte with acceptable precision and correctness.

Enzyme kinetics is the quantitative study of enzyme-catalysed reaction rates and the factors that influence enzyme activity.

An enzyme-linked conjugate is an antibody or other biomolecule attached to an enzyme that generates a measurable signal in diagnostic and analytical assays.

Epidemiology is the scientific study of disease distribution, causes and patterns within populations to inform prevention and public health strategies.

An epigenetic biomarker is a measurable epigenetic change, such as DNA methylation, that indicates disease status, prognosis or therapeutic response.

Epigenetics is the study of heritable changes in gene expression caused by mechanisms that do not alter the underlying DNA sequence.

Epinephrine Auto-Injector Use describes the correct administration of adrenaline using a prefilled device for the emergency treatment of severe allergic reactions.

Episodic compliance refers to inconsistent adherence to regulatory requirements, procedures or prescribed treatments over time.

Epistasis evaluation investigates how interactions between different genes influence biological traits, disease risk or therapeutic response.

Epitope mapping identifies the specific molecular regions of an antigen recognised by antibodies, receptors or immune cells.

An equipment qualification protocol defines the procedures and acceptance criteria for demonstrating that manufacturing equipment performs as intended.